Noemi Reguart

Noemi Reguart

UNVERIFIED PROFILE

Are you Noemi Reguart?   Register this Author

Register author
Noemi Reguart

Noemi Reguart

Publications by authors named "Noemi Reguart"

Are you Noemi Reguart?   Register this Author

71Publications

2286Reads

9Profile Views

Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer.

Lung Cancer 2019 Sep 24;135:151-160. Epub 2019 Jul 24.

CIBER de Enfermedades Respiratorias - CIBERES, Instituto de Salud Carlos III, Madrid, Spain; Grupo Colaborativo en Cáncer de Pulmón CIBERES-CIBERONC-SEPAR-Plataforma Biobanco Pulmonar, Spain; Respiratory Medicine, Hospital Universitari Parc Taulí, Sabadell, Spain; Department of Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.07.020DOI Listing
September 2019

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.

Clin Lung Cancer 2019 Jul 26;20(4):e421-e429. Epub 2019 Feb 26.

Pathology Department, Hospital del Mar, Barcelona, Spain; Cancer Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.008DOI Listing
July 2019

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?

J Thorac Oncol 2019 Jun 23;14(6):963-967. Epub 2019 Apr 23.

Gustave Roussy, Cancer Medicine Department, Villejuif, France; University Paris-Sud, Orsay, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.02.031DOI Listing
June 2019

Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.

Clin Lung Cancer 2019 May 4;20(3):e219-e223. Epub 2019 Mar 4.

Department of Medical Oncology, Hospital Clínic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.02.022DOI Listing
May 2019

PD-L1 expression testing in non-small cell lung cancer.

Ther Adv Med Oncol 2018 11;10:1758835918763493. Epub 2018 Apr 11.

Department of Medical Oncology, Hospital Clínic, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835918763493DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898658PMC
April 2018

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

J Thorac Oncol 2017 06;12(6):e78-e80

Medical Oncology, Hospital Clínic, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.02.014DOI Listing
June 2017

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Lung Cancer 2017 06 22;108:154-160. Epub 2017 Mar 22.

Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain; Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain; Molecular Oncology Research Foundation (MORe), Barcelona, Spain; Universitat Autònoma de Barcelona (UAB) Campus Can Ruti, Carretera de Canyet s/n, 08916 Badalona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.03.009DOI Listing
June 2017

Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.

Future Oncol 2015 28;11(8):1245-57. Epub 2015 Jan 28.

Medical Oncology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon.15.15
Publisher Site
http://dx.doi.org/10.2217/fon.15.15DOI Listing
February 2016

Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts.

Carcinogenesis 2015 Dec 7;36(12):1453-63. Epub 2015 Oct 7.

Unit of Biophysics and Bioengineering, School of Medicine, University of Barcelona, Barcelona 08036, Spain, CIBER de Enfermedades Respiratorias (CIBERES), Madrid, 28029, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgv146DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662832PMC
December 2015

Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.

Future Oncol 2015 19;11(2):267-77. Epub 2014 Sep 19.

Department of Medical Oncology, Hospital del Mar, Passeig Marítim 25-29, 08003 Barcelona; IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Dr Aiguader 88, 08003 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.214DOI Listing
September 2015

Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

Clin Lung Cancer 2015 Mar 21;16(2):e1-3. Epub 2014 Nov 21.

Catalan Institute of Oncology-Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2014.11.003DOI Listing
March 2015

Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.

Mol Cancer Res 2015 Jan 3;13(1):161-73. Epub 2014 Oct 3.

Unitat de Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. CIBER de Enfermedades Respiratorias, Bunyola, Spain.

View Article

Download full-text PDF

Source
http://mcr.aacrjournals.org/lookup/doi/10.1158/1541-7786.MCR
Publisher Site
http://dx.doi.org/10.1158/1541-7786.MCR-14-0155DOI Listing
January 2015

Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.

J Thorac Oncol 2014 Dec;9(12):1816-20

*Servei d'Oncologia Mèdica, Hospital del Mar, Barcelona, Spain; †Laboratori de Citogenètica Molecular, Department de Patologia, Hospital del Mar, Barcelona, Spain; ‡Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; §Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain; ‖Department de Patologia, Hospital del Mar, Barcelona, Spain; ¶Medical Oncology Department, Hospital de Mataró, Barcelona, Spain; #Medical Oncology Service, iCMHO, Hospital Clinic Barcelona, Barcelona, Spain; **Pathology Department, Hospital Lluís Alcanyís, Xàtiva, Spain; ††Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ‡‡Medical Oncology Department, Institut Català d'Oncologia (ICO), Hospital Universitari Dr. Josep Trueta, Girona, Spain; §§Department of Medical Sciences, University of Girona, Spain; ‖‖Pathology Department, Complejo Asistencial de Leon, Castilla y Leon, Spain; and ¶¶Medical Oncology Department, Institut Català d'Oncologia (ICO), Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/jto/2014/12000/Assessment_of_AL
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/JTO.0000000000000361DOI Listing
December 2014

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Lung Cancer 2014 May 2;84(2):161-7. Epub 2014 Mar 2.

Medical Oncology Department, Hospital Germans Trías i Pujol, Institut Català d'Oncologia-ICO, Badalona, Barcelona, Spain; Pangaea Biotech, Hospital Universitario Quirón, Dexeus, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.02.011DOI Listing
May 2014

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.

Expert Opin Biol Ther 2014 Jan 28;14(1):15-26. Epub 2013 Oct 28.

Professor, Head of Phase I-Early Clinical Trials Unit, Antwerp University Hospital UZA, Oncology Department , Wilrijkstraat 10, 2650 Edegem , Belgium +32 3 821 36 46 ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14712598.2013.843667DOI Listing
January 2014

Diarrhea associated with afatinib: an oral ErbB family blocker.

Expert Rev Anticancer Ther 2013 Jun 18;13(6):729-36. Epub 2013 Mar 18.

Graduate Institute of Oncology and Cancer Research Center, National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/era.13.31
Publisher Site
http://dx.doi.org/10.1586/era.13.31DOI Listing
June 2013

Sleeve lobectomy after induction chemoradiotherapy.

Eur J Cardiothorac Surg 2012 May 4;41(5):1052-8. Epub 2012 Jan 4.

General Thoracic Surgery Department, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezr184DOI Listing
May 2012

Determining the appropriate sleeve lobectomy versus pneumonectomy ratio in central non-small cell lung cancer patients: an audit of an aggressive policy of pneumonectomy avoidance.

Eur J Cardiothorac Surg 2011 Mar 24;39(3):352-9. Epub 2010 Dec 24.

General Thoracic Surgery Department, Thorax Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcts.2010.07.002DOI Listing
March 2011

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.

Cancer Manag Res 2010 Jun 1;2:143-56. Epub 2010 Jun 1.

Medical Oncology Service, ICMHO, Hospital Clinic Barcelona, Barcelona, Spain;

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004579PMC
June 2010

Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.

Eur J Cardiothorac Surg 2010 May 29;37(5):1168-74. Epub 2010 Jan 29.

Department of General Thoracic Surgery, Hospital Clinico y Provincial of Barcelona, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcts.2009.12.013DOI Listing
May 2010

BRCA1: a new genomic marker for non-small-cell lung cancer.

Clin Lung Cancer 2008 Nov;9(6):331-9

Medical Oncology Service, Catalan Institute of Oncology, ICO, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2008.n.048DOI Listing
November 2008

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway.

Clin Cancer Res 2006 Dec;12(24):7222-31

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0627DOI Listing
December 2006

Predicting the outcome of chemotherapy for lung cancer.

Curr Opin Pharmacol 2006 Aug 12;6(4):323-31. Epub 2006 Jun 12.

Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona, Spain, and Medical Oncology Unit, University of Messina, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2006.01.011DOI Listing
August 2006

Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.

Biochem Biophys Res Commun 2006 Apr 24;342(4):1228-32. Epub 2006 Feb 24.

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2006.02.084DOI Listing
April 2006

Future directions in the second-line treatment of non-small cell lung cancer.

Semin Oncol 2006 Feb;33(1 Suppl 1):S45-51

Medical Oncology Service, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2005.12.002DOI Listing
February 2006

The role of Wnt signaling in cancer and stem cells.

Future Oncol 2005 Dec;1(6):787-97

Catalan Institute of Oncology, Scientific Director of Oncology Research, Hospital Germans Trias i Pujol, Ctra Canyet, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.1.6.787DOI Listing
December 2005

Wnt2 as a new therapeutic target in malignant pleural mesothelioma.

Int J Cancer 2005 Nov;117(2):326-32

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.21160DOI Listing
November 2005

Wnt signaling in stem cells and non-small-cell lung cancer.

Clin Lung Cancer 2005 Jul;7(1):54-60

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLC.2005.n.022DOI Listing
July 2005

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations.

Future Oncol 2005 Jun;1(3):319-22

Catalan Institute of Oncology, Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, Badalona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14796694.1.3.319DOI Listing
June 2005

Efficacy of Wnt-1 monoclonal antibody in sarcoma cells.

BMC Cancer 2005 May 24;5:53. Epub 2005 May 24.

Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-5-53DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1164405PMC
May 2005

Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations.

Oncogene 2005 Apr;24(18):3054-8

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, 1600 Divisadero St, C322C, Box 1674, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1208511DOI Listing
April 2005

Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells.

Cancer Res 2005 Feb;65(3):743-8

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
February 2005

The promise of pharmacogenomics: gemcitabine and pemetrexed.

Oncology (Williston Park) 2004 Nov;18(13 Suppl 8):70-6

Medical Oncology Service, Hospital Germans Trias i Pujol, Badalona, Spain.

View Article

Download full-text PDF

Source
November 2004

Cloning and characterization of the promoter of human Wnt inhibitory factor-1.

Biochem Biophys Res Commun 2004 Oct;323(1):229-34

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2004.08.075DOI Listing
October 2004

Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma.

Biochem Biophys Res Commun 2004 Oct;323(4):1246-50

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2004.09.001DOI Listing
October 2004

Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells.

Oncogene 2004 Aug;23(36):6170-4

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1207844
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1207844DOI Listing
August 2004

An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth.

Cancer Res 2004 Aug;64(15):5385-9

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1674, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-1227DOI Listing
August 2004

Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.

Cancer Res 2004 Jul;64(14):4717-20

Thoracic Oncology Laboratory, Department of Surgery, Comprehensive Cancer Center, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-04-1389DOI Listing
July 2004

Molecular predictors of response to chemotherapy in lung cancer.

Semin Oncol 2004 Feb;31(1 Suppl 1):20-7

Medical Oncology Service, the Pathology Department, Hospital Germans Trias i Pujol, Insitut Català d'Oncologia, Badalona (Barcelona), Spain.

View Article

Download full-text PDF

Source
February 2004

DNA repair and cisplatin resistance in non-small-cell lung cancer.

Lung Cancer 2002 Dec;38(3):217-27

Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Barcelona, Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(02)00224-6DOI Listing
December 2002

Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon.

J Clin Oncol 2002 Oct;20(19):4032-9

Medical Oncology Department, Institut de Malalties Hemato-Oncològiques, University of Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.08.009DOI Listing
October 2002